A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2018
At a glance
- Drugs Abemaciclib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 18 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Jul 2018.
- 14 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
- 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.